New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?

Giuseppe Bronte, Marta Castiglia, Francesco Passiglia, Giuseppe Cicero, Daniele Fanale, Antonio Russo, Viviana Bazan, Antonio Galvano, Marc Peeters, Christian Rolfo, Nicola Silvestris, Antonio Giordano, Antonio Giordano, Christian Diego Rolfo, Giovanni Sortino

Research output: Contribution to journalArticlepeer-review

58 Citations (Scopus)

Abstract

Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents. Among these alterations KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Liquid biopsy, which helps to isolate circulating tumor DNA, is an innovative method to study both primary and acquired resistance to anti- EGFR monoclonal antibodies. However, high-sensitivity techniques should be used to enable the identification of a wide set of gene mutations related to resistance.
Original languageEnglish
Pages (from-to)24780-24796
Number of pages17
JournalOncotarget
Volume6
Publication statusPublished - 2015

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?'. Together they form a unique fingerprint.

Cite this